67 results about "Structured lipid" patented technology

The invention discloses a pet food with a synergistic anti-inflammatory function and a preparation method thereof, and the method comprises the following steps: preparing an anti-inflammatory nano-carrier, preparing an anti-inflammatory synergistic emulsion, emulsifying and dispersing active ingredients, tempering, extruding, puffing and drying, preparing probiotic particles, performing step-by-step vacuum spraying and the like. And a multi-level active component protection and delivery system is systematically constructed. Wherein the nanostructured lipid carrier and the microencapsulated ginger active extract are compounded according to a specific proportion, and a synergistic interaction system is formed through a fat source medium; and the probiotics are sprayed and added after being subjected to a multi-layer embedding and low-temperature granulation technology. The pet food prepared by the method comprises an anti-inflammatory synergistic composite unit and a probiotic particle unit, and experiments prove that the bioavailability of the core anti-inflammatory component reaches 52%, the in-vitro TNF-alpha inhibition rate reaches 65%, and the survival rate of probiotics exceeds 4.2 * 10 < 8 > CFU / g, so that the pet food is obviously superior to the traditional process, and the synergistic improvement of the anti-inflammatory effect, the component stability and the processing adaptability is realized.

The invention discloses a multilevel liver targeting drug delivery system based on ionizable amino lipid and a preparation method thereof, the system comprises the following components: target modified ionizable amino lipid, ionizable amino lipid, auxiliary lipid and structural lipid in a molar ratio of (10-30): (30-60): (5-40): (15-55), according to the system, nano lipid particles exist in a water-in-oil-in-water nano emulsion form; wherein the ionizable ammonia lipid is a compound with a structure as shown in a formula (I). The system is suitable for delivering nucleic acid, protein and other active pharmaceutical ingredients to the liver so as to improve the accuracy and treatment effect of drug delivery and reduce the side effects of non-target organs.

The purpose of the present invention is to provide: lipid nanoparticles useful as a nucleic acid delivery carrier; and a novel pH-sensitive cationic lipid for producing the lipid nanoparticles. The problem is solved by: a pH-sensitive cationic lipid comprising an asymmetric hydrocarbon chain; and lipid nanoparticles comprising the pH-sensitive cationic lipid as a constituent lipid.

The invention relates to the field of synthetic biology, in particular to a structural lipid, a preparation method thereof, a structural lipid composition containing the structural lipid and used for protecting liver and eyes, and a product for protecting liver and eyes. The preparation method comprises the following steps: carrying out reaction on mixed oil and lipase, and carrying out enzyme deactivation to prepare structural lipid; wherein the weight ratio of omega3 fatty acid to omega6 fatty acid to omega9 fatty acid in the oil material is (0.8-1.2): (0.8-1.2): (0.8-1.2). The lipase is adopted to carry out hydrolysis reaction on appropriate oil, sn-2 site fatty acid with the liver and eye protection effect can be prepared, and the sn-2 site fatty acid is small in molecular weight and beneficial to absorption.

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and / or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

A composition including ionizable lipids is provided. Methods of making the ionizable lipids are also provided. Also provided are compositions forming lipid nanoparticles, wherein the composition includes the ionizable lipid, a helper lipid, a structural lipid or sterol, and a polymer-conjugated lipid. Methods of using the ionizable lipid and lipid nanoparticles are also provided.

The invention provides a rucotinib phosphate nanostructure lipid carrier, a preparation method and application thereof, and a rucotinib phosphate composition, and belongs to the technical field of pharmaceutical preparations. According to the rucotinib phosphate nanostructure lipid carrier and the rucotinib phosphate composition provided by the invention, the solid lipid and the liquid lipid are compounded, and the anti-crystallization agent is introduced, so that the rucotinib phosphate is encapsulated in the nanostructure lipid carrier core formed by the solid lipid and the liquid lipid; the problem of unique crystallization caused by a pyrazole structure of rucotinib phosphate is solved, and the compound has the advantages of high encapsulation efficiency and good stability. According to the invention, the rucotinib phosphate nanostructure lipid carrier is uniformly dispersed in a dermatologically acceptable matrix to obtain a composition containing a therapeutically effective amount of rucotinib phosphate, and the composition shows significantly enhanced drug stability and skin retention ability, and reduces the risk of system exposure.

The present application relates to the technical field of nucleic acid drug preparation, and discloses a lipid nanoparticle based on asiatic acid and a preparation method and application thereof, the lipid nanoparticle is composed of ionizable cationic lipids, structural lipids, neutral lipids, PEG lipids and asiatic acid with a molar ratio of 10-85:20-60:1-30:0.1-10:0.1-50, and is used as a delivery carrier of nucleic acid drugs for delivering nucleic acid drugs. The present application innovatively uses natural product asiatic acid to partially replace the structural lipids (such as cholesterol) in the traditional LNP formula, significantly optimizes the micro morphology, and greatly enhances the transfection and expression efficiency of mRNA in vitro and in vivo. The mRNA vaccine based on the carrier can induce the body to produce high-titer specific antibodies and significantly enhance the cytotoxic T lymphocyte (CTL) killing activity. The LNP system performs outstandingly in the field of tumor immunoprevention and treatment, and shows superior conversion application potential and broad market prospects.

The invention belongs to the technical field of biochemical engineering, and particularly relates to a method for preparing medium-chain fatty glyceride through double-enzyme catalysis. The method provided by the invention comprises the following steps: firstly, catalyzing raw materials such as coconut oil to be completely hydrolyzed by utilizing lipase, and separating medium-chain fatty acid with the purity of more than or equal to 99.5% by adopting a molecular distillation cooling crystallization technology; then, high-purity fatty acid and glycerol are used as substrates, immobilized lipase is used as a catalyst, directional esterification is performed in a reactor provided with a dehydration membrane block, and the water activity of the system is controlled to be 0.1-0.3. The content of medium-chain fatty glyceride in the final product is higher than 98%, and the final product does not contain long-chain fatty acid impurities. The process is green and energy-saving, the catalyst can be recycled, the economical efficiency is good, and an innovative solution is provided for large-scale production of the high-purity structured lipid.

The invention relates to the technical field of progesterone sustained-release nanoparticle production, in particular to a progesterone sustained-release nanoparticle which comprises progesterone and further comprises solid lipid and liquid lipid according to the formula ratio of 1: 1.4: 1.2: 0.8. A preparation method of the progesterone sustained-release nanoparticle comprises raw material preparation of progesterone, solid lipid and liquid lipid and melt emulsification. The prepared progesterone lipid nanoparticles have high drug entrapment efficiency which can reach 77.48% at most, and have obvious drug sustained and controlled release performance, although the particle size of the nanoparticles is increased along with the increase of the content of liquid lipid-oleic acid in the lipid nanoparticles, the drug entrapment efficiency is improved, the in-vitro release of the drug is accelerated, and the progesterone lipid nanoparticles have good application prospects. According to the progesterone nanostructure lipid carrier, the drug content in the preparation process of the nanoparticles is improved, the drug encapsulation efficiency of the prepared progesterone nanostructure lipid carrier is reduced, but the drug loading capacity of the nanoparticles can be improved, and when the dosage reaches 20%, the drug loading capacity of the nanoparticles can reach 11.57%.

This invention discloses an oil-based nanostructured lipid carrier based on MLCT, its preparation method, and its application. The method includes mixing long-chain oil with decanoic acid triglyceride, adding immobilized lipase, vacuum drying, stirring, filtering, deacidification, and vacuum evaporation to obtain MLCT-structured lipids. Glyceryl monostearate is mixed with the MLCT-structured lipids and heated to form the oil phase. Trichosanthes kirilowii seed oil is mixed with ultrapure water and heated to form the aqueous phase. The aqueous and oil phases are then mixed, heated, ultrasonically broken up, and subjected to an ice bath to obtain the oil-based nanostructured lipid carrier. This invention replaces traditional small-molecule emulsifiers with natural oil bodies (OB) as emulsifiers, meeting consumer health needs while exhibiting excellent stability and safety; it also reduces the risk of chemically synthesized residues. Furthermore, the introduction of MLCT revolutionizes the digestibility of NLCs at the metabolic mechanism level. In vitro simulated digestion experiments show that the free fatty acid release rate is higher than 80%, providing a new solution for the development of functional food and drug delivery systems.

The invention discloses a method for making a sponge cake by completely replacing butter with oleogel, and belongs to the technical field of food processing. The butter in a traditional sponge cake formula is completely replaced with the oleogel according to the mass ratio of 100%. According to the oleogel, a pea protein-high methoxyl pectin electrostatic compound is used as a gel agent, a three-dimensional structured lipid network is constructed by regulating and controlling the pH value of a system and the concentration of pectin, a liquid oil phase is effectively fixed, and the oleogel has excellent structural stability, thixotropic restorability and thermal stability. In the stirring and baking process, the oleogel provides necessary mechanical support and keeps a batter bubble system and a cake tissue structure stable, so that the sponge cake which is ideal in specific volume, uniform in pore and soft in texture is obtained, and the quality of the sponge cake reaches the level equivalent to that of a traditional butter cake. Zero-trans and low-saturated-fat healthy fat replacement is achieved, meanwhile, the processing adaptability and sensory quality of the sponge cake are kept, and a new technical approach and application prospects are provided for development of healthy baked food.

The present application discloses PLPC-DB, an ultrapurified phospholipoproteomic composition derived from the supernatant of peripheral blood mononuclear cells (PBMCs). It comprises essential phospholipids, bioactive proteins, regulatory peptides, and intercellular signaling factors. The composition exceeds 99% purity through a multi-stage purification process combining high-speed centrifugation and selective ultrafiltration (1-50 kDa), followed by lyophilization. This process ensures structural stability for ≥24 months and inter-batch variability <2%. PLPC-DB supports reproducibility and molecular integrity in research and diagnostic settings. Key components include phosphatidylcholine and phosphatidylserine for membrane stabilization and intracellular signaling; structural and regulatory lipids for membrane biogenesis and immune-relevant components involved in antigen presentation, cytokine modulation, and membrane-associated signaling. These may include structurally defined molecules compatible with immunological evaluation in experimental and non-therapeutic settings. The composition is formulated for bioaccessible delivery via sublingual, endonasal, transdermal, and injectable routes, and is intended exclusively for non-therapeutic use in experimental and translational models.

The invention discloses a preparation method of a silybin nanostructure lipid carrier, which comprises the following steps: step 1, heating ethanol and silybin in a water bath, and uniformly stirring to obtain a silybin solution; dispersing a co-emulsifier in deionized water, and heating and stirring in a water bath to obtain a water phase; step 2, adding solid lipid, liquid lipid, a main emulsifier and a co-emulsifier into the silibinin solution, heating for melting, and uniformly stirring to obtain an oil phase; under the condition of constant-temperature stirring, transferring the oil phase into the water phase, mixing the solution, and shearing to obtain a coarse dispersion system; and 3, heating the coarse dispersion system to concentrate the coarse dispersion system into an emulsion. The silibinin nanostructure lipid carrier prepared by the invention can improve the solubility of silibinin, and is good in characterization performance; the preparation cost is controllable, and macro preparation can be realized; the silybin nano-structure lipid carrier can be used for effectively preventing acute liver injury caused by CCl4 of animals.

The invention relates to the technical field of nucleic acid medicine preparations, and discloses lipid nanoparticles based on asiatic acid and a preparation method and application thereof.The lipid nanoparticles are composed of ionizable cationic lipid, structural lipid, neutral lipid, PEG lipid and asiatic acid according to the molar ratio of (10-85): (20-60): (1-30): (0.1-10): (0.1-50) and serve as delivery carriers of nucleic acid medicine. For delivery of nucleic acid drugs. According to the invention, a natural product asiatic acid is creatively adopted to partially replace a structural lipid (such as cholesterol) in a traditional LNP formula, and the micromorphology of the LNP is obviously optimized, so that the in-vivo and in-vitro transfection and expression efficiency of mRNA is greatly enhanced. The mRNA vaccine constructed based on the vector can induce an organism to generate a high-titer specific antibody, and the killing activity of cytotoxic T lymphocytes (CTL) is remarkably enhanced. The LNP system has outstanding performance in the field of tumor immunoprophylaxis and treatment, and shows excellent transformation application potential and wide market prospect.

The application provides a kind of detection method and application of multiple functional structural lipids in infant biscuit, belong to food detection technical field. Including: after sample is pulverized, using n-hexane-isopropyl alcohol-methanol-1,4-dioxane mixed extraction liquid extraction, obtain crude extract; Using modified graphene / silica gel composite adsorbent for solid phase extraction purification, obtain the test solution; Using high performance liquid chromatography-double detector combination system for detection, wherein C18 chromatographic column is combined with optimized gradient elution program to realize baseline separation of three C52 structural lipids, separation degree is greater than or equal to 1.5, ultraviolet detector and evaporation light scattering detector are connected in series respectively for determination of high concentration and low concentration target. The application realizes simultaneous detection of OPO, OPL and LPL three functional structural lipids in infant biscuit for the first time, has the advantages of comprehensive detection material, complex applicable matrix, excellent separation effect, high sensitivity, simple operation and the like.

Provided is a lipid nanoparticle, which comprises an active component, an ionizable lipid, an auxiliary lipid, a structural lipid, and a polymer lipid. The polymer lipid accounts for 0-0.8 mol% of the total lipid existing in the lipid nanoparticle. The reduction in the content of the polymer lipid in the lipid nanoparticle can change the delivery specificity of the lipid nanoparticle, such that the lipid nanoparticle can target the spleen or immune cells.

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and / or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

The present invention relates to a material for local drug delivery and use thereof. Specifically provided is a nanoparticle composition. The nanoparticle composition comprises a cationic lipid, a PEG lipid, and a structural lipid, wherein the lipid component of the PEG lipid is 1.0-5.5 mol%, or a range between any two of the described values. The nanoparticle composition of the present invention is delivered only at the site of administration.

Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.

The application discloses an anti-wrinkle and firming composition suitable for multiple skin types and a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition contains, in mass parts, 2.5-9.5 parts of an active functional component, 5-10 parts of a targeted delivery carrier system and cosmetically acceptable adjuvants. The active functional component is composed of ginsenoside Rb1, green tea extract-white resveratrol compound and asiaticoside-dipotassium glycyrrhizinate compound, and the targeted delivery carrier system is a transdermal peptide modified liposome and a natural nano-structured lipid carrier. The application constructs a double-targeted delivery system according to different skin aging mechanisms and skin characteristics, realizes single formula adaptation to multiple skin types, improves the transdermal efficiency of active ingredients and the targeted enrichment effect on the dermis, has no carrier residue, and multiple components synergistically play the effects of anti-wrinkle and firming, soothing and protection, is safe, and can be widely applied to the preparation of anti-aging skin care products.

This invention, in some embodiments thereof, provides a core- shell nanoparticle including a lipid-PSMA conjugate, encapsulating a liquid oil-based core. The invention further provides aqueous compositions including the core-shell nanoparticles, and methods for using same, such as for the treatment of proliferative diseases associated with PSMA upregulated expression.

The invention discloses an emulsion type suppository practical for vaginal administration, and relates to the technical field of pharmaceutical preparations, the suppository is a solid at room temperature, and can be converted into a cream type preparation in situ under vaginal temperature and wetting conditions; the suppository is composed of active and pharmaceutically acceptable auxiliary materials, the auxiliary materials comprise structural lipid, an emulsifier, a gel matrix and a pH regulator, and a suppository body is softened at body temperature and mixed with body fluid to form a cream mixture easy to coat on the mucous membrane surface in situ. The transformation process avoids greasy feeling and local discomfort possibly brought by a traditional greasy suppository, and also eliminates the trouble that the prefabricated cream needs to be matched with a special administration device, so that the local medication experience of a patient is improved while the administration convenience is ensured. Besides, through reasonable selection of auxiliary materials, the cream formed through conversion can provide proper adhesion, and the retention time of the medicine at the action part can be prolonged.

The present disclosure provides an application of a medium-chain fatty acid mixed structural lipid in improving diet-induced disorders of glucose (Glu) and lipid metabolism. The medium-chain fatty acid mixed structural lipid includes capric lauric triglyceride and capric lauric diglyceride, and a mass percentage content ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure lipid is 1:1-1:4. In the present disclosure, it is found that adding medium-chain fatty acid mixed glyceride rich in lauric acid into high-energy feed can improve diet-induced disorders of Glu and lipid metabolism, including but not limited to reducing a serum Glu level, improving Glu homeostasis, reducing a serum low density lipoprotein cholesterol (LDL-C) level and improving expressions of genes related to Glu and lipid metabolism.

The invention provides a baricitinib nano-cream and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The baricitinib nano-cream provided by the invention comprises a cream matrix and a nano-structure lipid carrier dispersed in the cream matrix, the nano-structure lipid carrier comprises a solid lipid, a liquid lipid and a non-ionic emulsifier, and the types of the solid lipid and the liquid lipid are specifically limited, so that the content of the solid lipid and the liquid lipid in the nano-structure lipid carrier is increased, and the content of the non-ionic emulsifier in the nano-structure lipid carrier is increased. According to the present invention, the solid lipid provides the structure stability, the liquid lipid introduces the lattice defect, such that the solubility and the encapsulation efficiency of the baricitinib or the pharmaceutically acceptable salt thereof are improved so as to improve the release rate and the stability of the baricitinib nano-cream. The nanostructured lipid carrier is dispersed in the cream matrix, so that the permeability and adhesiveness of the baricitinib nanocream can be improved.

A lipid nanoparticle composition for delivery of genome editing ribonucleoprotein (RNP) includes a lipid component that encapsulates the genome editing ribronucleoprotein (RNP), wherein the lipid component includes an ionizable cationic lipid with a pK a > 6, at least one phospholipid, a structural lipid, and PEG-modified lipid.

This invention discloses a preparation process for medium- and short-chain structured lipids, belonging to the field of structured lipid preparation technology. Addressing the technical problems of existing enzymatic methods for preparing medium- and short-chain structured lipids, such as high enzyme dosage, high cost, long reaction cycle, and low butyric acid binding rate, this invention employs a two-step chemical synthesis method: First, using glycerol and an equal mass mixture of octanoic acid, capric acid, and lauric acid as raw materials, and tetrabutyl titanate as a catalyst (addition amount 0.15%–0.3%), the reaction is carried out at 150℃ for 2 hours and 200℃ for 2 hours under nitrogen protection to synthesize medium-chain triglycerides (MCTs). After neutralization, washing, and vacuum deacidification purification, the mixture is mixed with butyric acid at a molar ratio of 1:1.5–2.5 and acidified at -0.08–-0.1 MPa and 140–180℃ for 4 hours to introduce short-chain fatty acids. Finally, the target product is obtained by vacuum filtration through a 0.45 μm filter membrane. The total reaction time of this invention is only 8 hours, the product purity can reach 97.5%, the butyric acid binding rate is 12.5% ​​to 24.6%, no expensive lipase is required, the production cost is greatly reduced, and it is suitable for industrial continuous production.

Provided are a new gene drug delivery system based on a three-component lipid nanoparticle (LNP), and a preparation method therefor and the use thereof. The three-component LNP is composed of three ingredients: a cationic lipid, a structural lipid and a polymer-conjugated lipid. By means of precise ratio optimization, the three-component LNP maintains an efficient delivery performance while achieving component simplification. Compared with traditional four-component LNPs, the three-component LNP reduces the types of chemical components during preparation, thereby significantly reducing the complexity and cost of the production process, and making the three-component LNP more suitable for large-scale industrial production. In addition, due to the reduction in the types of components, the three-component LNP exhibits improved biocompatibility, reduced potential immunogenicity and toxicity risks, and higher safety.

The present invention relates to a novel ionizable sterol derivative and a lipid nanoparticle composition comprising same, in which a novel ionizable lipid synthesized on the basis of a sterol structure may simultaneously exhibit the roles of cholesterol components of ionizable lipids and structural lipids of existing lipid nanoparticles, and thus lipid nanoparticles composed thereof may be utilized as a more stable and effective drug delivery platform.